Skip to main content
Explore URMC

URMC Logo

menu
URMC / Labs / Zent Lab / Publications

Recent Publications

    1. VanDerMeid KR
    2. Elliott MR
    3. Baran AM
    4. Barr PM
    5. Chu CC
    6. Zent CS
    Cellular Cytotoxicity of Next Generation CD20 Monoclonal Antibodies.; Cancer immunology research. 2018 Aug 08.
    1. Archibald WJ
    2. Meacham PJ
    3. Williams AM
    4. Baran AM
    5. Victor AI
    6. Barr PM
    7. Sahasrahbudhe DM
    8. Zent CS
    Management of melanoma in patients with chronic lymphocytic leukemia.; Leukemia research; Vol 71. 2018 Jul 06.
    1. Mato AR
    2. Thompson M
    3. Allan JN
    4. Brander DM
    5. Pagel JM
    6. Ujjani CS
    7. Hill BT
    8. Lamanna N
    9. Lansigan F
    10. Jacobs R
    11. Shadman M
    12. Skarbnik AP
    13. Pu JJ
    14. Barr PM
    15. Sehgal AR
    16. Cheson BD
    17. Zent CS
    18. Tuncer HH
    19. Schuster SJ
    20. Pickens PV
    21. Shah NN
    22. Goy A
    23. Winter AM
    24. Garcia C
    25. Kennard K
    26. Isaac K
    27. Dorsey C
    28. Gashonia LM
    29. Singavi AK
    30. Roeker LE
    31. Zelenetz A
    32. Williams A
    33. Howlett C
    34. Weissbrot H
    35. Ali N
    36. Khajavian S
    37. Sitlinger A
    38. Tranchito E
    39. Rhodes J
    40. Felsenfeld J
    41. Bailey N
    42. Patel B
    43. Burns TF
    44. Yacur M
    45. Malhotra M
    46. Svoboda J
    47. Furman RR
    48. Nabhan C
    Real world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.; Haematologica. 2018 Jun 07.
    1. Mato AR
    2. Nabhan C
    3. Thompson MC
    4. Lamanna N
    5. Brander DM
    6. Hill B
    7. Howlett C
    8. Skarbnik A
    9. Cheson BD
    10. Zent C
    11. Pu J
    12. Kiselev P
    13. Goy A
    14. Claxton D
    15. Isaack K
    16. Kennard KH
    17. Timlin C
    18. Landsburg D
    19. Winter A
    20. Nasta SD
    21. Bachow SH
    22. Schuster SJ
    23. Dorsey C
    24. Svoboda J
    25. Barr P
    26. Ujjani CS
    Toxicities and outcomes of 621 ibrutinib-treated chronic lymphocytic leukemia patients in the United States: a real-world analysis.; Haematologica. 2018 Feb 01.
    1. Taylor RP
    2. Lindorfer MA
    3. Cook EM
    4. Beurskens FJ
    5. Schuurman J
    6. Parren PWHI
    7. Zent CS
    8. VanDerMeid KR
    9. Burack R
    10. Mizuno M
    11. Morgan BP
    Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9.; Clinical immunology (Orlando, Fla.); Vol 181. 2017 Aug.
    1. Williams AM
    2. Baran AM
    3. Meacham PJ
    4. Feldman MM
    5. Valencia HE
    6. Newsom-Stewart C
    7. Gupta N
    8. Janelsins MC
    9. Barr PM
    10. Zent CS
    Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies.; Leukemia & lymphoma. 2017 Jul 11.
    1. Murphy EJ
    2. Neuberg DS
    3. Rassenti LZ
    4. Hayes G
    5. Redd R
    6. Emson C
    7. Li K
    8. Brown JR
    9. Wierda WG
    10. Turner S
    11. Greaves AW
    12. Zent CS
    13. Byrd JC
    14. McConnel C
    15. Barrientos J
    16. Kay N
    17. Hellerstein MK
    18. Chiorazzi N
    19. Kipps TJ
    20. Rai KR
    Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia.; Leukemia; Vol 31(6). 2017 Jun.
    1. Helber MJ
    2. Moore JE
    3. Williams AM
    4. Meacham PJ
    5. Rothberg PG
    6. Zent CS
    Ibrutinib Therapy for Lymphoplasmacytic Lymphoma.; American journal of hematology. 2017 May 24.
    1. Grever MR
    2. Abdel-Wahab O
    3. Andritsos LA
    4. Banerji V
    5. Barrientos J
    6. Blachly JS
    7. Call TG
    8. Catovsky D
    9. Dearden C
    10. Demeter J
    11. Else M
    12. Forconi F
    13. Gozzetti A
    14. Ho AD
    15. Johnston JB
    16. Jones J
    17. Juliusson G
    18. Kraut E
    19. Kreitman RJ
    20. Larratt L
    21. Lauria F
    22. Lozanski G
    23. Montserrat E
    24. Parikh SA
    25. Park JH
    26. Polliack A
    27. Quest GR
    28. Rai KR
    29. Ravandi F
    30. Robak T
    31. Saven A
    32. Seymour JF
    33. Tadmor T
    34. Tallman MS
    35. Tam C
    36. Tiacci E
    37. Troussard X
    38. Zent CS
    39. Zenz T
    40. Zinzani PL
    41. Falini B
    Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.; Blood; Vol 129(5). 2017 Feb 02.
    1. Zent CS
    2. Elliott MR
    Maxed out macs: physiologic cell clearance as a function of macrophage phagocytic capacity.; The FEBS journal. 2016 Nov 14.
    1. Williams AM
    2. Zent CS
    3. Janelsins MC
    What is known and unknown about chemotherapy-related cognitive impairment in patients with haematological malignancies and areas of needed research.; British journal of haematology; Vol 174(6). 2016 Sep.
    1. Cook EM
    2. Lindorfer MA
    3. van der Horst H
    4. Oostindie S
    5. Beurskens FJ
    6. Schuurman J
    7. Zent CS
    8. Burack R
    9. Parren PW
    10. Taylor RP
    Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.; Journal of immunology (Baltimore, Md. : 1950); Vol 197(5). 2016 Sep 01.
    1. Zent CS
    2. Bowen DA
    3. Conte MJ
    4. LaPlant BR
    5. Call TG
    Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study.; Leukemia & lymphoma; Vol 57(7). 2016 Jul.
    1. Zent CS
    Chronic lymphocytic leukemia and proteomics: protein profiles and links with disease progression still need validation.; Leukemia & lymphoma; Vol 57(5). 2016 May.
    1. Zent CS
    2. Victoria Wang X
    3. Ketterling RP
    4. Hanson CA
    5. Libby EN
    6. Barrientos JC
    7. Call TG
    8. Chang JE
    9. Liu JJ
    10. Calvo AR
    11. Lazarus HM
    12. Rowe JM
    13. Luger SM
    14. Litzow MR
    15. Tallman MS
    A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908).; American journal of hematology; Vol 91(3). 2016 Mar.
    1. Lindorfer MA
    2. Cook EM
    3. Tupitza JC
    4. Zent CS
    5. Burack R
    6. de Jong RN
    7. Beurskens FJ
    8. Schuurman J
    9. Parren PW
    10. Taylor RP
    Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells.; Molecular immunology; Vol 70. 2016 Feb.
    1. Zent CS
    CLL: an acquired immunodeficiency disease.; Blood; Vol 128(15). 2016 Jan 13.
    1. Mato AR
    2. Nabhan C
    3. Barr PM
    4. Ujjani CS
    5. Hill BT
    6. Lamanna N
    7. Skarbnik AP
    8. Howlett C
    9. Pu JJ
    10. Sehgal AR
    11. Strelec LE
    12. Vandegrift A
    13. Fitzpatrick DM
    14. Zent CS
    15. Feldman T
    16. Goy A
    17. Claxton DF
    18. Bachow SH
    19. Kaur G
    20. Svoboda J
    21. Nasta SD
    22. Porter D
    23. Landsburg DJ
    24. Schuster SJ
    25. Cheson BD
    26. Kiselev P
    27. Evens AM
    Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.; Blood; Vol 128(18). 2016 Jan 03.
    1. Church AK
    2. VanDerMeid KR
    3. Baig NA
    4. Baran AM
    5. Witzig TE
    6. Nowakowski GS
    7. Zent CS
    Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages.; Clinical and experimental immunology; Vol 183(1). 2016 Jan.
    1. Bowen DA
    2. Rabe KG
    3. Schwager SM
    4. Slager SL
    5. Call TG
    6. Viswanatha DS
    7. Zent CS
    Infectious lymphadenitis in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: a rare, but important, complication.; Leukemia & lymphoma; Vol 56(2). 2015 Feb.
    1. Zent CS
    2. Call TG
    3. Bowen DA
    4. Conte MJ
    5. LaPlant BR
    6. Witzig TE
    7. Ansell SM
    8. Weiner GJ
    Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates.; Leukemia & lymphoma; Vol 56(8). 2015.
    1. Stilgenbauer S
    2. Furman RR
    3. Zent CS
    Management of chronic lymphocytic leukemia.; American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting. 2015.
    1. Zent CS
    2. Burack WR
    Mutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1, SF3B1, and TP53.; Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program; Vol 2014(1). 2014 Dec 5.
    1. Barr PM
    2. Zent CS
    Infection in chronic lymphocytic leukemia: parsimony has its limits.; Leukemia & lymphoma; Vol 55(12). 2014 Dec.
    1. Barr PM
    2. Zent CS
    The ABC of CLL: Etiology of cytopenias is important in staging and management; Leuk Lymphoma; Vol 55, pp. 12-19. 2014 Jan 01.
    1. Conte MJ
    2. Bowen DA
    3. Wiseman GA
    4. Rabe KG
    5. Slager SL
    6. Schwager SM
    7. Call TG
    8. Viswanatha DS
    9. Zent CS
    Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.; Leukemia & lymphoma; Vol 55(9). 2014 Sep.
    1. Call TG
    2. Norman AD
    3. Hanson CA
    4. Achenbach SJ
    5. Kay NE
    6. Zent CS
    7. Ding W
    8. Cerhan JR
    9. Rabe KG
    10. Vachon CM
    11. Hallberg EJ
    12. Shanafelt TD
    13. Slager SL
    Incidence of chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis using the 2008 guidelines.; Cancer; Vol 120(13). 2014 Jul 01.
    1. Zent CS
    2. Taylor RP
    3. Lindorfer MA
    4. Beum PV
    5. LaPlant B
    6. Wu W
    7. Call TG
    8. Bowen DA
    9. Conte MJ
    10. Frederick LA
    11. Link BK
    12. Blackwell SE
    13. Veeramani S
    14. Baig NA
    15. Viswanatha DS
    16. Weiner GJ
    17. Witzig TE
    Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells.; American journal of hematology; Vol 89(7). 2014 Jul.
    1. Slager SL
    2. Zent CS
    Genetic risk of chronic lymphocytic leukemia: a tale of two cities.; Leukemia & lymphoma; Vol 55(4). 2014 Apr.
    1. Baig NA
    2. Taylor RP
    3. Lindorfer MA
    4. Church AK
    5. LaPlant BR
    6. Pettinger AM
    7. Shanafelt TD
    8. Nowakowski GS
    9. Zent CS
    Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.; Journal of immunology (Baltimore, Md. : 1950); Vol 192(4). 2014 Feb 15.
    1. Greipp PT
    2. Smoley SA
    3. Viswanatha DS
    4. Frederick LS
    5. Rabe KG
    6. Sharma RG
    7. Slager SL
    8. Van Dyke DL
    9. Shanafelt TD
    10. Tschumper RC
    11. Zent CS
    Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis; Br J Haematol; Vol 163(3), pp. 326-33. 2013 Jan 01.
    1. Shanafelt T
    2. Lanasa MC
    3. Call TG
    4. Beaven AW
    5. Leis JF
    6. LaPlant B
    7. Bowen D
    8. Conte M
    9. Jelinek DF
    10. Hanson CA
    11. Kay NE
    12. Zent CS
    Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).; Cancer; Vol 119(21). 2013 Nov 01.
    1. Charbonneau B
    2. Wang AH
    3. Maurer MJ
    4. Asmann YW
    5. Zent CS
    6. Link BK
    7. Ansell SM
    8. Weiner GJ
    9. Ozsan N
    10. Feldman AL
    11. Witzig TE
    12. Cunningham JM
    13. Dogan A
    14. Habermann TM
    15. Slager SL
    16. Novak AJ
    17. Cerhan JR
    CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis.; Cancer immunology, immunotherapy : CII; Vol 62(9). 2013 Sep.
    1. Parikh SA
    2. Rabe KG
    3. Call TG
    4. Zent CS
    5. Habermann TM
    6. Ding W
    7. Leis JF
    8. Schwager SM
    9. Hanson CA
    10. Macon WR
    11. Kay NE
    12. Slager SL
    13. Shanafelt TD
    Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients.; British journal of haematology; Vol 162(6). 2013 Sep.
    1. Witzig TE
    2. Wiseman GA
    3. Maurer MJ
    4. Habermann TM
    5. Micallef IN
    6. Nowakowski GS
    7. Ansell SM
    8. Colgan JP
    9. Inwards DJ
    10. Porrata LF
    11. Link BK
    12. Zent CS
    13. Johnston PB
    14. Shanafelt TD
    15. Allmer C
    16. Asmann YW
    17. Gupta M
    18. Ballas ZK
    19. Smith BJ
    20. Weiner GJ
    A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma.; American journal of hematology; Vol 88(7). 2013 Jul.
    1. Gonsalves WI
    2. Zent CS
    3. Pulido JS
    4. Patnaik MM
    Visual loss in early-stage chronic lymphocytic leukemia.; Journal of clinical oncology : official journal of the American Society of Clinical Oncology; Vol 31(17). 2013 Jun 10.
    1. Shanafelt TD
    2. Ramsay AG
    3. Zent CS
    4. Leis JF
    5. Tun HW
    6. Call TG
    7. LaPlant B
    8. Bowen D
    9. Pettinger A
    10. Jelinek DF
    11. Hanson CA
    12. Kay NE
    Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL).; Blood; Vol 121(20). 2013 May 16.
    1. Kourelis TV
    2. Gertz M
    3. Zent C
    4. Lacy M
    5. Kyle R
    6. Kapoor P
    7. Zeldenrust S
    8. Buadi F
    9. Witzig T
    10. Hayman S
    11. Lust J
    12. Russell S
    13. Lin Y
    14. Rajkumar VS
    15. Kumar S
    16. Leung N
    17. Dingli D
    18. Dispenzieri A
    Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma.; American journal of hematology; Vol 88(5). 2013 May.
    1. Zent CS
    2. Wu W
    3. Bowen DA
    4. Hanson CA
    5. Pettinger AM
    6. Shanafelt TD
    7. Kay NE
    8. Leis JF
    9. Call TG
    Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphpocytic leukemia with alemtuzumab and rituximab; Leuk Lymphoma; Vol 54(3), pp. 476-82. 2013 Jan 01.
    1. Shanafelt TD
    2. Call TG
    3. Zent CS
    4. Leis JF
    5. LaPlant B
    6. Bowen DA
    7. Roos M
    8. Laumann K
    9. Ghosh AK
    10. Lesnick C
    11. Lee MJ
    12. Yang CS
    13. Jelinek DF
    14. Erlichman C
    15. Kay NE
    Phase 2 trial of daily, oral polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphpocytic leukemia; Cancer; Vol 119(2), pp. 363-70. 2013 Jan 01.
    1. Baig NA
    2. Taylor RP
    3. Lindorfer MA
    4. Church AK
    5. LaPlant B
    6. Pavey ES
    7. Nowakowski GS
    8. Zent CS
    Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement; Leuk Lymphoma; Vol 53(11), pp. 2218-27. 2012 Jan 01.
    1. Charbonneau B
    2. Maurer MJ
    3. Fredericksen ZS
    4. Zent CS
    5. Link BK
    6. Novak AJ
    7. Ansell SM
    8. WeinerGJ WA
    9. Witzig TE
    10. Dogan A
    11. Slager SL
    12. Habermann TM
    13. Cerhan JR
    Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma; Am J Hematol; Vol 87(9), pp. 880-5. 2012 Jan 01.
    1. Lindorfer MA
    2. Wiestner A
    3. Zent CS
    4. Taylor RP
    Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?; Oncoimmunology; Vol 1(6), pp. 959-61. 2012 Jan 01.
    1. Taylor RP
    2. Lindorfer MA
    3. Zent CS
    Anti-CD20 antibody therapy for B-cell lymphomas; N Engl J Med; Vol 367(9), pp. 876-7. 2012 Jan 01.
    1. Zent CS
    Improving quality of life in chronic lymphocytic leukemia; Leuk Lymphoma; Vol 53(7), pp. 1247-8. 2012 Jan 01.
    1. Shanafelt TD
    2. Kay NE
    3. Rabe KG
    4. Inwards DJ
    5. Zent CS
    6. Leis JF
    7. Schwager SM
    8. Thompson CA
    9. Bowen DA
    10. Witzig TE
    11. Slager SL
    12. Call TG
    Hematologist/oncologist disease-specific expertise and survival: lessions from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL); Cancer; Vol 118(7), pp. 1827-37. 2012 Jan 01.
    1. Gustafson MP
    2. Abraham RS
    3. Lin Y
    4. Wu W
    5. Gastineau DA
    6. Zent CS
    7. Dietz AB
    Association of an increased frequency of CD14+ HLA-DR lo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL); Br J Haematol; Vol 156(5), pp. 674-6. 2012 Jan 01.
    1. Zent CS
    2. Smith BJ
    3. Ballas ZK
    4. Wooldridge JE
    5. Link BK
    6. Call TG
    7. Shanafelt TD
    8. Bowen DA
    9. Kay NE
    10. Witzig TE
    11. Weinier GJ
    Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia; Leuk Lymphoma; Vol 53(2), pp. 211-7. 2012 Jan 01.
    1. Shanafelt TD
    2. Kay NE
    3. Rabe KG
    4. Call TG
    5. Zent CS
    6. Schwager SM
    7. Leis JF
    8. Jelinek DF
    9. Slager SL
    10. Hanson CA
    Survival of patients with clinically identified monoclonal B-cell lymphocytosis (MBL) relative to the age- and sex-matched general population; Leukemia; Vol 26(2), pp. 373-6. 2012 Jan 01.
    1. Shanafelt TD
    2. Kay NE
    3. Rabe KG
    4. Call TG
    5. Zent CS
    6. Schwager SM
    7. Leis JF
    8. Jelinek DF
    9. Slager SL
    10. Hanson CA
    Survival of patients with clinically identified monoclonal B-cell lymphocytosis (MBL) relative to the age- and sex-matched general population.; Leukemia; Vol 26(2). 2012 Feb.
    1. Mraz M
    2. Zent CS
    3. Church AK
    4. Jelinek DF
    5. Wu X
    Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin alpha-4-beta-1 (VLA-4) with natalizumab can overcome this resistance; Br J Haematol; Vol 155(1), pp. 53-64. 2011 Jan 01.
    1. Zent CS
    Multi-parameter prognostication in chronic lymphocytic leukemia; Leuk Lymphoma; Vol 52(10), pp. 1823-4. 2011 Jan 01.
    1. Maurer MJ
    2. Cerhan JR
    3. Katzmann JA
    4. Link BK
    5. Allmer C
    6. Zent CS
    7. Call TG
    8. Rabe KG
    9. Hanson CA
    10. Kay NE
    11. Slager SL
    12. Witzig TE
    13. Shanafelt TD
    Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia; Blood; Vol 118(10), pp. 2821-6. 2011 Jan 01.
    1. Zent CS
    2. Kay NE
    Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach; Leuk Lymphoma; Vol 52(8), pp. 1425-34. 2011 Jan 01.
    1. Chen D
    2. Kettering RP
    3. Hanson CA
    4. Colgan JP
    5. Zent CS
    6. Viswanatha DS
    A case of hairy cell leukemia with CCND1-IGH translocation: indolent non-nodal mantle cell lymphoma revisited; Am J Surg Pathol; Vol 35(7), pp. 1080-4. 2011 Jan 01.
    1. Zent CS
    2. Polliack A
    3. Tadmor T
    FISHing for answers in proliferation centers of chronic lymphocytic leukemia lymph nodes; Leuk Lymphoma; Vol 52(6), pp. 946-7. 2011 Jan 01.
    1. Shanafelt TD
    2. Drake MT
    3. Maurer MJ
    4. Allmer C
    5. Rabe KG
    6. Slager SL
    7. Weiner GH
    8. Call TG
    9. Link BK
    10. Zent CS
    11. Kay NE
    12. Hanson CA
    13. Witzig TE
    14. Cerhan JR
    Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia; Blood; Vol 117(5), pp. 1492-8. 2011 Jan 01.
    1. Gutierrez A
    2. Arendt BK
    3. Tschumper RC
    4. Kay NE
    5. Zent CS
    6. Jelinek DF
    Differentiation of chronic lymphocytic leukemia B-cells into immunoglobulin secreting cells decreases LEF-1 expression; PLoS One; Vol 6(10). 2011 Jan 01.
    1. Shanafelt T
    2. Zent C
    3. Byrd J
    4. Erlichman C
    5. LaPlant B
    6. Ghosh A
    7. Call T
    8. Villalona-Calero M
    9. Jelinek D
    10. Bowen D
    11. Laumann K
    12. Wu W
    13. Hanson C
    14. Kay N
    Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia; Leuk Lymphoma; Vol 51(12), pp. 2222-9. 2010 Jan 01.
    1. Shanafelt TD
    2. Rabe KG
    3. Kay NE
    4. Zent CS
    5. Jelinek DF
    6. Reinalda MS
    7. Schwager SM
    8. Bowen DA
    9. Slager SL
    10. Hanson CA
    11. Call TG
    Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia.; Cancer; Vol 116(20). 2010 Oct 15.
    1. Shanafelt TD
    2. Rabe KG
    3. Kay NE
    4. Zent CS
    5. Jelinek DF
    6. Reinalda MS
    7. Schwager SM
    8. Bowen DA
    9. Slager SL
    10. Hanson CA
    11. Call TG
    Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia; Cancer; Vol 116(20), pp. 4777-87. 2010 Jan 01.
    1. Zent CS
    Cell-mediated immunity in chronic lymphocytic leukemia; Leuk Lymphoma; Vol 51(10), pp. 1775-6. 2010 Jan 01.
    1. Jevremovic D
    2. Dronca RS
    3. Morice WG
    4. McPhail ED
    5. Kurtin PG
    6. Zent CS
    CD5+ B-cell lymphoproliferative disorders: Beyond chronic lymphocytic leukemia and mantle cell lymphoma; Leuk Res; Vol 34(9), pp. 1235-8. 2010 Jan 01.
    1. Zent CS
    Chronic Lymphocytic Leukemia in the Elderly: Who Should be Treated?; Am Soc Clin Oncol Ed. 2010 Jan 01.
    1. Shanafelt TD
    2. Rabe KG
    3. Kay NE
    4. Zent CS
    5. Call TG
    6. Slager SL
    7. Bowen DA
    8. Schwager SM
    9. Nowakowski GS
    Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chornic lymphocytic leukemia; Leuk Lymphoma; Vol 51(7), pp. 1233-40. 2010 Jan 01.
    1. Bauer PR
    2. Zent CS
    3. Aubry MC
    4. Ryu JH
    Recurrent fevers, cough, and pulmonary opacities in a middle-aged man; Chest; Vol 137(6), pp. 1465-9. 2010 Jan 01.
    1. Zent CS
    Time to test CLL p53 function; Blood; Vol 115(21), pp. 4154-5. 2010 Jan 01.
    1. Zent CS
    2. LaPlant BR
    3. Johnston PB
    4. Call TG
    5. Habermann TM
    6. Micallef IN
    7. Witzig TE
    The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation; Cancer; Vol 116(9), pp. 2201-7. 2010 Jan 01.
    1. Kay NE
    2. Wu W
    3. Kabat B
    4. LaPlant B
    5. Lin TS
    6. Byrd JC
    7. Jelinek DF
    8. Grever MR
    9. Zent CS
    10. Call TG
    11. Shanafelt TD
    Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia; Cancer; Vol 116(9), pp. 2180-7. 2010 Jan 01.
    1. Bowen DA
    2. Call TG
    3. Shanafelt TD
    4. Kay NE
    5. Schwager RM
    6. Reinalda MS
    7. Rabe KG
    8. Slager SL
    9. Zent CS
    Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone; Leuk Lymphoma; Vol 51(4), pp. 620-7. 2010 Jan 01.
    1. Zent CS
    2. Kay NE
    Autoimmune complications in chronic lymphocytic leukaemia (CLL); Best Pract Res Clin Haematol; Vol 23(1), pp. 47-59. 2010 Jan 01.
    1. Van Dyke DL
    2. Shanafelt TD
    3. Call TG
    4. Zent CS
    5. Smoley SA
    6. Rabe KG
    7. Schwager SM
    8. Sonbert JC
    9. Slager SL
    10. Kay NE
    A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemia; Br J Haematol; Vol 148(4), pp. 544-50. 2010 Jan 01.
    1. Zent CS
    2. Van Dyke DL
    Detection of recurrent chromosomal defects in chronic lymphocytic leukemia/small lymphocytic lymphoma: innovations and applications; Leuk Lymphoma; Vol 51(2), pp. 186-7. 2010 Jan 01.
    1. Dronca RS
    2. Jevremovic D
    3. Hanson CA
    4. Rabe KG
    5. Shanafelt TD
    6. Morice WG
    7. Call TG
    8. Kay NE
    9. Collins CS
    10. Schwager SM
    11. Slager SL
    12. Zent CS
    CD5-positive chronic B-cell lymphoproliferative disorders: diagnosis and prognosis of a heterogeneous disease entity; Cytometry B Clin Cytom; Vol 58(Suppl 1), pp. 35-41. 2010 Jan 01.
    1. Ding W
    2. Nowakowski GS
    3. Knox TR
    4. Boysen JC
    5. Maas ML
    6. Schwager SM
    7. Wu W
    8. Wellik LE
    9. Dietz AB
    10. Ghosh AK
    11. Secreto CR
    12. Medina KL
    13. Shanafelt TD
    14. Zent CS
    15. Call TG
    16. Kay NE
    Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression; Br J Haematol; Vol 147(4), pp. 471-83. 2009 Jan 01.
    1. Pardanani A
    2. Tefferi A
    3. Litzow MR
    4. Zent C
    5. Hogan WJ
    6. McClure RF
    7. Viswanatha D
    Chronic myeloid leukemia with p190BCR-ABL: prevalence, morphology, tyrosine kinase inhibitor response, and kinase domain mutation analysis.; Blood; Vol 114(16). 2009 Oct 15.
    1. Shanafelt TD
    2. Byrd JC
    3. LaPlant B
    4. Zent CS
    5. Call T
    6. Secreto C
    7. Grever MR
    8. Lin TS
    9. Kay NE
    Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia; Br J Haematol; Vol 146(6), pp. 660-4. 2009 Jan 01.
    1. Shanafelt TD
    2. Call TG
    3. Zent CS
    4. LaPlant B
    5. Bowen DA
    6. Roos M
    7. Secreto CR
    8. Ghosh AK
    9. Kabat BF
    10. Lee MJ
    11. Yang CS
    12. Jelinek DF
    13. Erlichman C
    14. Kay NE
    Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia; J Clin Oncol; Vol 27(23), pp. 3808-14. 2009 Jan 01.
    1. Shanafelt TD
    2. Kay NE
    3. Rabe KG
    4. Call TG
    5. Zent CS
    6. Maddocks K
    7. Jenkins G
    8. Jelinek DF
    9. Morice WG
    10. Boysen J
    11. Schwager S
    12. Bowen D
    13. Slager SL
    14. Hanson CA
    Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia; J Clin Oncol; Vol 27(24), pp. 3959-63. 2009 Jan 01.
    1. Zent CS
    2. Ding W
    3. Reinalda MS
    4. Schwager SM
    5. Hoyer JD
    6. Bowen DA
    7. Jelinek DF
    8. Tschumper RC
    9. Call TG
    10. Shanafelt TD
    11. Kay NE
    12. Slager SL
    Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis; Leuk Lymphoma; Vol 50(8), pp. 1261-8. 2009 Jan 01.
    1. Zent CS
    2. Shanafelt T
    Management of autoimmune cytopenia complicating chronic lymphocytic leukemia; Leuk Lymphoma; Vol 50(6), pp. 863-4. 2009 Jan 01.
    1. Shanafelt TD
    2. Kay NE
    3. Jenkins G
    4. Call TG
    5. Zent CS
    6. Jelinek DF
    7. Morice WG
    8. Boysen J
    9. Zakko L
    10. Schwager S
    11. Slager SL
    12. Hanson CA
    B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome; Blood; Vol 113(18), pp. 4188-96. 2009 Jan 01.
    1. Nowakowski GS
    2. Hoyer JD
    3. Shanafelt TD
    4. Zent CS
    5. Call TG
    6. Bone ND
    7. Laplant B
    8. Dewald GW
    9. Tschumper RC
    10. Jelinek DF
    11. Witzig TE
    12. Kay NE
    Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia; J Clin Oncol; Vol 27(11), pp. 1844-9. 2009 Jan 01.
    1. Shanafelt TD
    2. Bowen DA
    3. Venkat C
    4. Slager SL
    5. Zent CS
    6. Kay NE
    7. Reinalda M
    8. Tun H
    9. Sloan JA
    10. Call TG
    The physician-patient relationship and quality of life: lessons from chronic lymphocytic leukemia; Leuk Res; Vol 33(2), pp. 263-70. 2009 Jan 01.
    1. Awan FT
    2. Kay NE
    3. Davis ME
    4. Wu W
    5. Geyer SM
    6. Leung N
    7. Jelinek DF
    8. Tschumper RC
    9. Secreto CR
    10. Lin TS
    11. Grever MR
    12. Shanafelt TD
    13. Zent CS
    14. Call TG
    15. Heerema NA
    16. Lozanski G
    17. Byrd JC
    18. Lucas DM
    Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab.; Blood; Vol 113(3). 2009 Jan 15.
    1. Shanafelt TD
    2. Jenkins G
    3. Call TG
    4. Zent CS
    5. Slager S
    6. Bowen DA
    7. Schwager S
    8. Hanson CA
    9. Jelinek DF
    10. Kay NE
    Validation of a new prognostic index for patients with chronic lymphocytic leukemia; Cancer; Vol 115(2), pp. 363-72. 2009 Jan 01.
    1. Zent CS
    2. Secreto CR
    3. LaPlant BR
    4. Bone ND
    5. Call TG
    6. Shanafelt TD
    7. Jelinek DF
    8. Tschumper RC
    9. Kay NE
    Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab; Leuk Res; Vol 32(12), pp. 1849-56. 2008 Jan 01.
    1. Zent CS
    2. Call TS
    3. TD TR
    4. Jelinek DF
    5. Bowen DA
    6. Secreto CR
    7. Laplant BR
    8. Kabat BF
    9. Kay NE
    Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab; Cancer; Vol 113(8), pp. 2110-8. 2008 Jan 01.
    1. Shanafelt TD
    2. Kay NE
    3. Cell TG
    4. Zent CS
    5. Jelinek DF
    6. LaPlant B
    7. Morice WG
    8. Hanson CA
    MBL or CLL: which classification best categorizes the clinical course of patients with an absolute lymphocyte count , greater than or equal to 5 x 10e9/L but a B-cell lymphocyte count less than or equal to 5 x 10e9/L?; Leuk Res; Vol 32(9), pp. 1458-61. 2008 Jan 01.
    1. Holtan SG
    2. Porrata LF
    3. Colgan JP
    4. Zent CS
    5. Habermann TM
    6. Markovic SN
    mTOR inhibitor monotherapy is insufficient to suppress viremia and disease progression in Epstein-Barr virus-driven lymphoproliferative disorders (EBV-LPD).; American journal of hematology; Vol 83(8). 2008 Aug.
    1. Palmer S
    2. Hanson CA
    3. Zent CS
    4. Porrata LF
    5. Laplant B
    6. Geyer SM
    7. Markovic SN
    8. Call TG
    9. Bowen DA
    10. Jelinek DF
    11. Kay NE
    12. Shanafelt TD
    Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia; Br J Haematol; Vol 141(5), pp. 607-14. 2008 Jan 01.
    1. Zent CS
    2. Ding W
    3. Schwager SM
    4. Reinalda MS
    5. Hoyer JD
    6. Jelinek DF
    7. Tschumper RC
    8. Bowen DA
    9. Call TG
    10. Shanafelt TD
    11. Kay NE
    12. Slager SL
    The prognostic significant of cytopenia in chronoc lymphocytic leukaemia/small lymphocytic lymphoma; Br J Haematol; Vol 141(5), pp. 615-21. 2008 Jan 01.
    1. Hogan WJ
    2. Zent CS
    Stem cell transplant for chronic lymphocytic leukemia/small lymphocytic lymphoma; Leuk Lymphoma; Vol 49(5), pp. 835-6. 2008 Jan 01.
    1. Hogan WJ
    2. Zent CS
    Stem cell transplant for chronic lymphocytic leukemia/small lymphocytic lymphoma.; Leukemia & lymphoma; Vol 49(5). 2008 May.
    1. Shanafelt TD
    2. Geyer SM
    3. Bone ND
    4. Tschumper RC
    5. Witzig TE
    6. Nowakowski GS
    7. Zent CS
    8. Call TG
    9. Laplant B
    10. Dewald GW
    11. Jelinek DF
    12. Kay NE
    CD49d expression is an independent predictor of overall survival i npatients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential; Br J Haematol; Vol 140(5), pp. 537-46. 2008 Jan 01.
    1. Zent CS
    The role of alemtuzumab in the treatment of chronic lymphocytic leukemia.; Leukemia & lymphoma; Vol 49(2). 2008 Feb.
    1. Tschumper RC
    2. Geyer SM
    3. Campbell ME
    4. Kay NE
    5. Shanafelt TD
    6. Zent CS
    7. Nowakowski GS
    8. Call TG
    9. Dewald GW
    10. Jelinek DF
    Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients; J Clin Invest; Vol 118(1), pp. 306-15. 2008 Jan 01.
    1. Thurmes P
    2. Call T
    3. Slager S
    4. Zent C
    5. Jenkins G
    6. Schwager S
    7. Bowen D
    8. Kay NE
    9. Shanafelt T
    Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia; Leuk Lymphoma; Vol 49(1), pp. 49-56. 2008 Jan 01.
    1. Bowen DA
    2. Call TG
    3. Jenkins GD
    4. Zent CS
    5. Schwager SM
    6. Van Dyke DL
    7. Jelinek DF
    8. Kay NE
    9. Shanafelt TD
    Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features; Leuk Lymphoma; Vol 48(12), pp. 2412-7. 2007 Jan 01.
    1. Browning RL
    2. Geyer SM
    3. Johnson AJ
    4. Jelinek DF
    5. Tschumper RC
    6. Call TG
    7. Shanafelt TD
    8. Zent CS
    9. Bone ND
    10. Dewald GW
    11. Lin TS
    12. Heerema NA
    13. Gever MR
    14. Kay NE
    15. Byrd JC
    16. Lucas DM
    Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia; Leuk Res; Vol 49(1), pp. 49-56. 2007 Jan 01.
    1. Maddocks-Christianson K
    2. Slager SL
    3. Zent CS
    4. Reinalda M
    5. Call TG
    6. Habermann TM
    7. Bowen DA
    8. Hoyer JD
    9. Schwager S
    10. Jelinek DF
    11. Kay NE
    12. Shanafelt TD
    Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia; Br J Haematol; Vol 139(3), pp. 398-404. 2007 Jan 01.
    1. Shanafelt TD
    2. Bowen D
    3. Venkat C
    4. Slager SL
    5. Zent CS
    6. Kay NE
    7. Reinalda M
    8. Sloan JA
    9. Call TG
    Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients; Br J Haematol; Vol 139(2), pp. 255-64. 2007 Jan 01.
    1. Zent CS
    2. Kay NE
    Chronic lymphocytic leukemia: biology and current treatment; Curr Oncol Rep; Vol 9(5), pp. 345-52. 2007 Jan 01.
    1. Shanafelt TD
    2. Lin T
    3. Geyer SM
    4. Zent CS
    5. Leung N
    6. Kabat B
    7. Bowen D
    8. Grever MR
    9. Byrd JC
    10. Kay NE
    Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia; Cancer; Vol 109(11), pp. 2291-8. 2007 Jan 01.
    1. Ding W
    2. Zent CS
    Diagnosis and management of autoimmune complications of chronic lymphocytic leukemia/small lymphocytic lymphoma; Clin Adv Hematol Oncol; Vol 5(4), pp. 257-61. 2007 Jan 01.
    1. Nowakowski GS
    2. Hoyer JD
    3. Shanafelt TD
    4. Geyer SM
    5. LaPlant BR
    6. Call TG
    7. Jelinek DF
    8. Zent CS
    9. Kay NE
    Using smudge cells on routine blood smears to predict clinical outcome in chronic lymphocytic leukemia: a universally available prognostic test; Mayo Clin Proc; Vol 82(4), pp. 449-53. 2007 Jan 01.
    1. Rockacy J
    2. Viozzi CF
    3. Zent CS
    Mantle cell lymphoma presenting as a slowly enlarging lesion of the floor of mouth in a healthy 72 year old: report of a case; J Oral Maxillofac Surg; Vol 65(2), pp. 333-7. 2007 Jan 01.
    1. Kay NE
    2. Geyer SM
    3. Call TG
    4. Shanafelt TD
    5. Zent CS
    6. Jelinek DF
    7. Tschumper R
    8. Bone ND
    9. Dewald GW
    10. Lin TS
    11. Heerema NA
    12. Smith L
    13. Grever MR
    14. Byrd JC
    Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia; Blood; Vol 109(2), pp. 405-11. 2007 Jan 01.
    1. Zent CS
    2. Polliack A
    Staging chronic lymphocytic leukemia (CLL) for prognosis at diagnosis; Leuk Lymphoma; Vol 47(12), pp. 2433-4. 2006 Jan 01.
    1. Shanafelt TD
    2. Witzig TE
    3. Fink SR
    4. Jenkins RB
    5. Paternoster SF
    6. Smoley SA
    7. Stockero KJ
    8. Nast DM
    9. Flynn HC
    10. Tschumper RC
    11. Geyer S
    12. Zent CS
    13. Call TG
    14. Jelinek DF
    15. Kay NE
    Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia; J Clin Oncol; Vol 24(28), pp. 4634-41. 2006 Jan 01.
    1. Zent CS
    Chronic B-cell lymphoproliferative disorders: how many diseases?; Leuk Lymphoma; Vol 47(10), pp. 2006-7. 2006 Jan 01.
    1. Shanafelt TD
    2. Byrd JC
    3. Call TG
    4. Zent CS
    5. Kay NE
    Narrative review: initial management for chronic lymphocytic leukemia; Ann Intern Med; Vol 145(6), pp. 435-47. 2006 Jan 01.
    1. Lee HB
    2. Pulido JS
    3. Buettner H
    4. Salomao D
    5. Zent CS
    6. Link TP
    Intravascular B-cell lymphoma (angiotropic lymphoma) with choroidal involvement; Arch Ophthalmol; Vol 124(9), pp. 1357-9. 2006 Jan 01.
    1. Zent CS
    2. Call TG
    3. Hogan WJ
    4. Shanafelt TD
    5. Kay NE
    Update on risk-stratified management for chronic lymphocytic leukemia; Leuk Lymphoma; Vol 47(9), pp. 1738-46. 2006 Jan 01.
    1. Zent CS
    Autoimmunity and chronic lymphocytic leukemia; Leuk Lymphoma; Vol 47(8), pp. 1443-4. 2006 Jan 01.
    1. Nora EH
    2. Hamacher KL
    3. Zent CS
    4. Ghosh AK
    Indolent systemic mastocytosis as the cause of a long history of unexplained hypotensive episodes; South Med J; Vol 99(8), pp. 876-9. 2006 Jan 01.
    1. Osborn NK
    2. Ustundag Y
    3. Zent CS
    4. Wiesner RH
    5. Rosen CB
    6. Narayanan MK
    Factor XII deficiency acquired by orthotopic liver transplantation: case report and review of the literature; Am J Transplant; Vol 6(7), pp. 1743-5. 2006 Jan 01.
    1. Fink SR
    2. Smoley SA
    3. Stockero KJ
    4. Paternoster SF
    5. Thorland EC
    6. Van Dyke DL
    7. Shanafelt TD
    8. Zent CS
    9. Call TG
    10. Kay NE
    11. Dewald GW
    Loss of TP53 due to rearrangements involving chromosome region 17p10 approximately p12 in chronic lymphocytic leukemia; Cancer Genet Cytogenet; Vol 167(2), pp. 177-81. 2006 Jan 01.
    1. Stockero KJ
    2. Fink SR
    3. Smoley SA
    4. Paternoster SF
    5. Shanafelt TD
    6. Call TG
    7. Zent CS
    8. Van Dyke DL
    9. Kay NE
    10. Dewald GW
    Metaphase cells with normal G-bands have cryptic interstitial deletions in 13q14 detectable by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia; Cancer Genet Cytogenet; Vol 166(2), pp. 152-6. 2006 Jan 01.
    1. Shanafelt TD
    2. Lee YK
    3. Call TG
    4. Nowakowski GS
    5. Dingli D
    6. Zent CS
    7. Kay NE
    Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies; Leuk Res; Vol 30(6), pp. 707-12. 2005 Jan 01.
    1. Nowakowski GS
    2. Dewald GW
    3. Hoyer JD
    4. Paternoster SF
    5. Stockero KJ
    6. Fink SR
    7. Smoley SA
    8. Remstein ED
    9. Phyliky RL
    10. Call TG
    11. Shanafelt TD
    12. Kay NE
    13. Zent CS
    Interphase fluorescence in situ hybridization with an IGH probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukaemia; Br J Haematol; Vol 130(1), pp. 36-42. 2005 Jan 01.
    1. Nowakowski GS
    2. Call TG
    3. Morice WG
    4. Kurtin PJ
    5. Cook RJ
    6. Zent CS
    Clinical significance of monoclonal B cells in cerebrospinal fluid; Cytometry B Clin Cytom; Vol 63(1), pp. 23-7. 2005 Jan 01.
    1. Zent CS
    2. Kay NE
    Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia; Curr Oncol Rep; Vol 6(5), pp. 348-54. 2004 Jan 01.
    1. Kohli M
    2. Zent C
    3. Hutchins LF
    4. Safar M
    5. Dotson P
    6. Mehta P
    The academic hematology-oncology firm: a model for postgraduate cancer education; J Cancer Educ; Vol 19(1), pp. 45-9. 2004 Jan 01.
    1. Zent CS
    2. Chen JB
    3. Kurten RC
    4. Kaushal GP
    5. Lacy HM
    6. Schichman SA
    Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium; Leuk Res; Vol 28(5), pp. 495-507. 2004 Jan 01.
    1. Kyasa MJ
    2. Hazlett L
    3. Parrish RS
    4. Schichman SA
    5. Zent CS
    Veterans with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have a markedly increased rate of second malignancy, which is the most common cause of death; Leuk Lymphoma; Vol 45(3), pp. 507-13. 2004 Jan 01.
    1. Zent CS
    2. Kay NE
    Update on monoclonal antibody therapy in chronic lymphocytic leukemia; Clin Adv Hematol Oncol; Vol 2(2), pp. 107-13. 2004 Jan 01.
    1. Kyasa MJ
    2. Parrish RS
    3. Schichman SA
    4. Zent CS
    Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma; Am J Hematol; Vol 74(1), pp. 1-8. 2003 Jan 01.
    1. Zent CS
    2. Zhan FG
    3. Schichman SA
    4. Bumm K
    5. Lin P
    6. Chen JB
    7. Shaughnessy JD
    The distinct gene expression profiles of chronic lymphocytic leukemia and multiple myeloma suggest different anti-apoptotic mechanisms but predict only some differences in phenotype; Leuk Res; Vol 27(9), pp. 765-74. 2003 Jan 01.
    1. Monson T
    2. Schichman SA
    3. Zent CS
    Linezolid-induced pure red blood cell aplasia; Clin Infect Dis; Vol 35(3), pp. 29-31. 2002 Jan 01.
    1. Kohli M
    2. Fink LM
    3. Spencer JH
    4. Zent CS
    Advanced prostate cancer activates coagulation: a controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer; Blood Coagul Fibrinolysis; Vol 13(1), pp. 1-5. 2002 Jan 01.
    1. Joseph L
    2. Scott MA
    3. Schichman SA
    4. Zent CS
    Localized herpes simplex lymphadenitis mimicking large-cell (Richter's) transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma; Am J Hematol; Vol 68(4), pp. 287-91. 2001 Jan 01.
    1. Zent CS
    2. Kyasa MJ
    3. Evans R
    4. Schichman SA
    Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data; Cancer; Vol 92(5), pp. 1325-30. 2001 Jan 01.
    1. Zent C
    Anemia and chronic disease; US Medicine; Vol 37(5 Suppl), pp. 5-8. 2001 Jan 01.
    1. Kohli M
    2. Schichman SA
    3. Fink L
    4. Zent CS
    Use of HFE mutation analysis for hereditary hemochromatosis: the need for physician education in the translation of basic science to clinical practice; South Med J; Vol 93(5), pp. 469-71. 2000 Jan 01.
    1. Govindarajan R
    2. Baxter D
    3. Wilson C
    4. Zent C
    Vancomycin-induced thrombocytopenia.; American journal of hematology; Vol 62(2). 1999 Oct.
    1. Zent CS
    2. Ratajczak J
    3. Ratajczak MZ
    4. Anastasi J
    5. Hoffman PC
    6. Gewirtz AM
    Relationship between megakaryoctye mass and serum thrombopoietin levels as revealed by a case of cyclic amegakaryocytic thrombocytopenic purpura; Br J Haematol; Vol 105(2), pp. 452-8. 1999 Jan 01.
    1. Zent CS
    2. Wilson CS
    3. Tricot G
    4. Jagannath S
    5. Siegel D
    6. Desikan KR
    7. Munshi N
    8. Bracy D
    9. Barlogie B
    10. Butch AW
    Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation; Blood; Vol 91(9), pp. 3518-23. 1998 Jan 01.
    1. Zent C
    2. Rowley JD
    3. Nucifora G
    Rearrangements of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: in vitro and in vivo studies; Leukemia; Vol 3(11 Suppl), pp. 273-8. 1997 Jan 01.
    1. Zent C
    2. Kim N
    3. Hiebert S
    4. Zhang DE
    5. Tenen DG
    6. Rowley JD
    7. Nucifora G
    Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression nof co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigneic properties; Current Topics in Microbiology & Immunology; Vol 211, pp. 243-52. 1996 Jan 01.
    1. Zent CS
    2. Mathieu C
    3. Claxton DF
    4. Zhang DE
    5. Tenen DG
    6. Rowley JD
    7. Nucifora G
    The chimeric genes AML1/MDS1 and AML1/EAP inhibit AML1B activation at the CSF1R promoter, but only AML1/MDS1 has tumor-promoter properties; Proc Natl Acad Sci; Vol 93(3), pp. 1044-8. 1996 Jan 01.
    1. Zent C
    2. Smith P
    Drug allergy; S AFr Med J; Vol 84(5), pp. 281-286. 1994 Jan 01.
    1. Zent CS
    Toxicity of anti-tuberculous medication; S. Afr J of Epidemiology and Infection; Vol 9(1), pp. 5-9. 1994 Jan 01.
    1. Zent CS
    2. Allin R
    3. Folb PI
    Prediction of amikacin dose requirements in neutropenic patients with haematological disease; S. Afr Med J; Vol 82(11), pp. 853-854. 1993 Jan 01.